Possibility and prospects of using bamlanivimab in patients with COVID-19


DOI: https://dx.doi.org/10.18565/pharmateca.2021.1.17-19

K.B. Mirzaev (1), D.A. Sychev (2)

1) Russian Medical Academy of Continuous Professional Education, Moscow, Russia, https://orcid.org/0000-0002-9307-4994; 2) Russian Medical Academy of Continuous Professional Education, Moscow, Russia, http://orcid.org/0000-0002-4496-3680
Currently, there is insufficient scientific evidence to recommend the routine use of bamlanivimab for the treatment of outpatients with COVID-19. An interim analysis of the phase II randomized placebo-controlled BLAZE-1 trial demonstrates the potential clinical benefit of bamlanivimab for outpatients with mild to moderate COVID-19, and its effectiveness in preventing the development of COVID-19 among medical personnel and residents of nursing homes.
Keywords: COVID-19, bamlanivimab

Бионика Медиа